EGFR-mutated lung cancer

Close up shot of the target from a dart game
Biotech

Taiho and Cullinan secure lung cancer victory to challenge J&J

Taiho and Cullinan racked up a second phase 3 victory for their EGFR inhibitor, teeing up the partners to challenge J&J in the lung cancer niche.
Nick Paul Taylor Aug 13, 2026 6:00am
Apple trees in an orchard

BlossomHill eyes $112M IPO harvest to fund Tagrisso challenger

Aug 3, 2026 9:18am
Field of flowers with a rainbow behind

BlossomHill eyes IPO to grow taller in crowded cancer fields

Jul 17, 2026 12:08pm
ASCO

ASCO: BMS' bispecific ADC puts TROP2 drugs on notice

Jun 2, 2026 8:00am
Blue race track
Favicon Fierce Pharma

Merck grows more ambitious about 'workhorse' TROP2 ADC

Oct 20, 2025 4:00pm
Summit
Favicon Fierce Pharma

Summit's global PD-1xVEGF data show new promising OS trend

Sep 7, 2025 3:30am